Ceftaroline Label Needs Clarity On Lack Of MRSA Data For CABP, Panel Says
Executive Summary
Labeling for Forest Laboratories' ceftaroline fosamil must specify that the antibiotic has not been clinically evaluated to treat methicillin-resistant Staphylococcus aureus in patients with community-acquired bacterial pneumonia, members of the Anti-Infective Drugs Advisory Committee told FDA Sept 7.